FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washingto

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

n, D.C. 20549	OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 2. Issuer Name and Ticker or Trading Symbol 1. Name and Address of Reporting Person* Aguestive Therapeutics, Inc. [AQST] Wargacki Stephen Director 10% Owner Officer (give title Other (specify 3. Date of Earliest Transaction (Month/Day/Year) below) below) (Middle) (Last) (First) 05/05/2023 SVP, Research & Development C/O AQUESTIVE THERAPEUTICS, INC. 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable 30 TECHNOLOGY DRIVE Line) X Form filed by One Reporting Person (Street) Form filed by More than One Reporting WARREN NJ 07059 Person Rule 10b5-1(c) Transaction Indication (Citv) (State) (Zip) Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2. Transaction Date 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 1. Title of Security (Instr. 3) 2A. Deemed 5. Amount of 6. Ownership 7. Nature of Execution Date. Transaction Securities Form: Direct Indirect (Month/Day/Year) if any (Month/Day/Year) Code (Instr. 8) Beneficially Owned Following (D) or Indirect Beneficial Ownership Reported (Instr. 4) (A) or (D) neaction(s) Code ν Amount Price (Instr. 3 and 4) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of 3. Transaction Date 3A. Deemed 5. Number 6. Date Exercisable and Title and Amount 8. Price of 9. Number of 11. Nature Conversion Ownership Execution Date, Transaction Derivative **Expiration Date** of Securities Derivative derivative of Indirect (Month/Day/Year Underlying Derivative Security (Instr. 3 and 4) Security (Instr. 3) or Exercise if any (Month/Day/Year) Code (Instr. Derivative (Month/Day/Year) Security Securities Form: Beneficial Price of Derivative Beneficially Owned Direct (D) or Indirect 8) (Instr. 5) Ownership (Instr. 4) Acquired Following Reported Transaction(s) (Instr. 4) Security (A) or Disposed (I) (Instr. 4) of (D) (Instr.

Explanation of Responses:

1. Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Aquestive ("Company") common stock. The PSUs have a three-year Performance Period, and, to the extent earned, will vest 100% on the third anniversary of the grant date, subject to the grantee's continued employment or other service with the Company or any Subsidiary from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the three-year Performance Period is subject to increase or decrease based on the results of the Performance Price The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period.

Date

(D)

Expiration

05/05/2026

Remarks:

Performance

Stock Units

/s/ Lori Braender, as Attorney-05/09/2023 In-Fact

** Signature of Reporting Person Date

Amount Number

67,500

\$0

67,500

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

05/05/2023

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

3. 4 and 5)

(A)

67.500

ν